List of Excipients in Branded Drug CIPRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	CIPRO	ciprofloxacin hydrochloride and hydrocortisone	0065-8531	ACETIC ACID
Alcon Laboratories Inc	CIPRO	ciprofloxacin hydrochloride and hydrocortisone	0065-8531	BENZYL ALCOHOL
Alcon Laboratories Inc	CIPRO	ciprofloxacin hydrochloride and hydrocortisone	0065-8531	HYDROCHLORIC ACID
Alcon Laboratories Inc	CIPRO	ciprofloxacin hydrochloride and hydrocortisone	0065-8531	LECITHIN, SOYBEAN

Generic Drugs Containing CIPRO

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	CORN OIL
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	HYPROMELLOSES
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CIPRO?

# Of NDCs	Excipient

Excipients Strategy and Commercial Opportunities for CIPRO (Ciprofloxacin)

Last updated: February 26, 2026

What is the role of excipients in CIPRO formulations?

Excipients in CIPRO (ciprofloxacin) formulations stabilize the active pharmaceutical ingredient (API), facilitate manufacturing, improve bioavailability, and enhance patient compliance. Standard formulations include oral tablets, oral suspension, and intravenous (IV) solutions.

How are excipient choices optimized for CIPRO?

Oral Tablets

• Binders: Microcrystalline cellulose (MCC), povidone. They facilitate compression and maintain tablet integrity.
• Disintegrants: Croscarmellose sodium, sodium starch glycolate. They promote rapid tablet disintegration for quick absorption.
• Lubricants: Magnesium stearate. They prevent sticking during manufacturing.
• Fillers/diluents: Lactose monohydrate, dicalcium phosphate. These bulk up the tablet and aid processing.

Oral Suspension

• Suspending agents: Xanthan gum, carboxymethyl cellulose. They maintain uniform dispersion.
• Sweeteners: Sucrose, sorbitol, to improve palatability.
• Flavoring agents: Fruit flavors like cherry or orange.

IV Formulations

• Solubilizers: Polyethylene glycol (PEG), poloxamers enhance solubility.
• Preservatives: Methylparaben, chlorobutanol prevent microbial growth.
• pH adjusters: Hydrochloric acid or sodium hydroxide to optimize stability.

What are the key considerations in excipient selection?

• Regulatory acceptability: Excipients must meet pharmacopeial standards (USP, Ph. Eur.).
• Compatibility: Excipients must not interact adversely with CIPRO or degrade the API.
• Patient safety: Excipients should be non-toxic and suitable for all patient populations.

What are the commercial opportunities related to excipient development?

Innovation in Excipients for CIPRO

• Enhanced bioavailability: Using cation-exchange resins or nanocarriers to improve absorption.
• Taste-masking: Developing advanced flavors and coating techniques for pediatric formulations.
• Stability enhancements: Novel antioxidants or stabilizers to extend shelf life, especially for tropical climates.

Contract Manufacturing and Custom Formulations

• Outsourcing excipient optimization to contract manufacturing organizations (CMOs) with expertise in microbiological control and stability studies.
• Developing niche formulations (e.g., sustained-release, combination products) with specialized excipients.

Patent and Market Expansion Opportunities

• Patent protection based on unique excipient combinations or delivery systems.
• Expanding into over-the-counter (OTC) or pediatric markets through formulations with targeted excipients.

Regulatory and Market Trends

• Emphasis on excipients with Generally Recognized As Safe (GRAS) status.
• Adoption of excipients that reduce manufacturing costs while maintaining formulation robustness.

How do current patents influence excipient strategies for CIPRO?

Patent landscapes reveal limited protection on specific excipient combinations for CIPRO, opening opportunities for innovative formulations. Companies investing in novel excipients may secure market exclusivity for combination products or new delivery systems.

Summary of Excipients and Market Dynamics

Formulation	Typical Excipients	Market Trend
Oral Tablets	MCC, povidone, croscarmellose, magnesium stearate, lactose	Focus on bioavailability and patient compliance
Oral Suspension	Xanthan gum, sucrose, flavor agents	Pediatric and generics segments
IV Solutions	PEG, methylparaben, pH adjusters	Specialized hospital use, biosimilar growth

Key Takeaways

• Excipients in CIPRO formulations are chosen based on stability, bioavailability, manufacturability, and patient safety.
• Innovation opportunities include bioavailability enhancement, taste-masking, and shelf-life stability improvements.
• Contract manufacturing services offer avenues for customized formulations and niche product development.
• Patent protection is limited on specific excipient combinations, enabling potential market entry pathways.
• Regulatory trends favor excipients with established safety profiles, reducing development risk.

FAQs

1. What are the most common excipients in CIPRO oral tablets?
Microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and lactose monohydrate.

2. How can excipients improve CIPRO's bioavailability?
By using solubilizers, nanocarriers, or bioavailability enhancers that improve dissolution and absorption.

3. Are there opportunities for flavoring innovation in CIPRO suspensions?
Yes, developing pediatric-friendly flavors and taste-masking techniques enhances compliance and market share.

4. What regulatory considerations impact excipient selection?
Excipients must meet pharmacopeial standards, have GRAS status, and demonstrate non-interaction with CIPRO.

5. How do patent landscapes influence excipient development for CIPRO?
Limited patent coverage on specific excipient combinations creates opportunities for innovative formulations and market entry.

---

References

[1] U.S. Pharmacopeia. (2022). USP-NF standards for excipients.
[2] European Pharmacopoeia Commission. (2022). General chapters on excipients.
[3] Kato, T., et al. (2018). Enhanced bioavailability of ciprofloxacin using nanocarrier systems. Journal of Pharmaceutical Sciences., 107(2), 451-460.
[4] Smith, R. L., & Jones, M. E. (2020). Excipient innovation for improved drug delivery. Pharmaceutical Technology.